SCHEMBL12282928

SCHEMBL12282928

NN(Cl)c1ccc(OC(F)(F)F)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.41
MAPT P10636 2/20 0.40
EPHX2 P34913 1/20 0.40
KDM4E B2RXH2 1/20 0.40
NISCH Q9Y2I1 1/20 0.39
MAOB P27338 1/20 0.38
AOC3 Q16853 1/20 0.38
ALDH1A1 P00352 1/20 0.38
DHFR P00374 1/20 0.38
GPR3 P46089 1/20 0.37
SERPINE1 P05121 1/20 0.37
GRIN2B Q13224 1/20 0.36
TUBB4A P04350 1/20 0.36
TUBB P07437 1/20 0.36
TUBA3C P0DPH7 1/20 0.36
TUBA1B P68363 1/20 0.36
TUBA4A P68366 1/20 0.36
TUBB4B P68371 1/20 0.36
TUBB3 Q13509 1/20 0.36
TUBB2A Q13885 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12294729 0.79 DHFR (0.43) MAPTEPHX2KDM4ENISCHDHFR
SCHEMBL254957 0.76 MAPT (0.56) TSHRMAPTEPHX2KDM4ENISCH
SCHEMBL29268186 0.75 EPHX2 (0.41) MAPTEPHX2KDM4ENISCHMAOB
SCHEMBL2056111 0.74 ALDH1A1 (0.50) TSHRMAPTEPHX2ALDH1A1DHFR
SCHEMBL8386558 0.73 EPHX2 (0.47) TSHRMAPTEPHX2KDM4ESERPINE1
SCHEMBL10697279 0.73 MAPT (0.47) TSHRMAPTEPHX2KDM4EALDH1A1
SCHEMBL28980342 0.72 EPHX2 (0.46) TSHREPHX2DHFRSERPINE1SLC6A4
SCHEMBL15521000 0.71 CA1 (0.52) MAPTKDM4EAOC3ALDH1A1L3MBTL1
SCHEMBL16710496 0.71 SERPINE1 (0.47) MAPTEPHX2KDM4EALDH1A1GPR3
SCHEMBL9091199 0.71 SERPINE1 (0.47) MAPTEPHX2KDM4EALDH1A1GPR3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9024041-B2 P38 MAP kinase inhibitors RESPIVERT LTD. (GB) 2015-05-05 US disclosed
US-20130040962-A1 P38 MAP Kinase Inhibitors RESPIVERT LTD (GB) 2013-02-14 US disclosed
WO-2011124930-A1 P38 MAP KINASE INHIBITORS RESPIVERT LIMITED (GB) 2011-10-13 WO disclosed
CN-1025811-C Pesticidal method using N-phenyl pyrazoles MAY & BAKER LTD (GB) 1994-09-07 CN disclosed
CN-1025582-C Azole pesticides SCHERING AGROCHEMICALS LTD (GB) 1994-08-10 CN disclosed
CN-1049341-A AZOLE PESTICIDES SCHERING AGROCHEMICALS LTD (GB) 1991-02-20 CN disclosed
CN-86108643-A Insecticidal method using N-phenylpyrazoles 1987-07-29 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130040962-A1 P38 MAP Kinase Inhibitors MAPK15, MAPK1, MAP3K15 TSHR 3231/4885MAPT 890/4885EPHX2 2144/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.